Introduction

Knee osteoarthritis is a common and often painful condition that affects many people across the UK. It causes discomfort, stiffness, and makes everyday activities more difficult, which can seriously affect quality of life. In the search for better treatment options, new therapies like Arthrosamid injections have come onto the scene. But who is actually suitable for this treatment? In this article, we’ll explore who can benefit from Arthrosamid, looking at eligibility, typical patient symptoms, what rules out treatment, recent research, and how specialists decide who should have this injection.

Who Is Eligible for Arthrosamid Injection?

Arthrosamid is a type of injectable gel made from polyacrylamide, designed to help relieve knee osteoarthritis symptoms by cushioning and protecting the joint. It’s a relatively new option and is typically offered to adults diagnosed with knee osteoarthritis who haven’t found enough relief through lifestyle changes or standard painkillers.

Common criteria for eligibility include:

• A confirmed diagnosis of knee osteoarthritis through scans and physical examination
• Persistent knee pain and difficulty despite non-surgical treatments
• Willingness and ability to attend follow-up appointments after the injection

Certain conditions mean Arthrosamid isn’t suitable, such as:

• Inflammatory diseases like rheumatoid arthritis
• Skin infections or issues near the knee
• Allergies to any part of the injection
• Severe deformities or instability in the knee

As one review notes, “Polyacrylamide (PAAG) hydrogel is a novel compound that has recently become available in the UK market under the name Arthrosamid to treat osteoarthritis (OA).” This framework supports clinicians in selecting appropriate candidates who stand to gain most from the treatment.

Typical Symptoms: When Should You Consider Arthrosamid?

People who might benefit from Arthrosamid often experience ongoing knee pain, swelling, and struggles with basic movements—like walking, climbing stairs or standing for long periods. These problems usually continue despite trying treatments like physiotherapy, painkillers, or weight management.

Before receiving Arthrosamid, it’s essential to have a thorough assessment by a specialist. Research supports this approach, showing “statistically significant data … at both 52 weeks and 13 months, indicating efficacy of PAAG hydrogel at one year post injection.” If your knee symptoms are persistent and affecting daily life, a specialist assessment can help decide if Arthrosamid is a suitable option.

Treatment Alternatives and Why Patient Selection Matters

Arthrosamid is just one option among many for knee osteoarthritis. Others include physiotherapy, oral pain medications, weight loss programmes, corticosteroid injections, hyaluronic acid injections, or—when necessary—surgery.

Choosing the right treatment for each patient is crucial. Not everyone will benefit from Arthrosamid, and using it inappropriately might do more harm than good. Research shows that, “In a Randomised Control Trial (RCT) numerically superior data was identified compared to hyaluronic acid.” It’s also reassuring to know that “Injection of PAAG hydrogel intraarticularly into the knee has been shown to be safe with no long-lasting adverse events reported.”

Further studies confirm that Arthrosamid “offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited.” In fact, it “showed the highest patient acceptable symptom state rates (72%, 54%, and 42% at 3, 6, and 12 months),” though differences at 12 months were not statistically significant. Experts suggest Arthrosamid “may be a complementary option in individualised osteoarthritis management.”

Longer-term results are encouraging too. One study found that “single injections of 6 ml intra-articular iPAAG are well tolerated and continue to provide clinically relevant and statistically significant effectiveness at 3 years after treatment.” Plus, significant improvements in pain and function were maintained over this time.

While Arthrosamid is being explored in NHS trials, it’s also available privately, highlighting both growing interest and the importance of careful, professional patient selection.

How Do Clinicians Decide if Arthrosamid Is Right for You?

If you’re being considered for Arthrosamid, the process usually starts with a thorough consultation. This includes a detailed medical history, physical examination, and imaging tests like X-rays or MRI scans to assess your knee’s condition.

A team of specialists—often including orthopaedic surgeons and musculoskeletal doctors—work together to make sure you are the right fit for this treatment. For example, clinicians like Professor Paul Lee, with vast experience in orthopaedics, play a key role in guiding patient care. Centres such as MSK Doctors focus on providing a supportive environment where patient safety, education, and shared decision-making come first.

Conclusion

Arthrosamid injections represent an exciting new option for some people with knee osteoarthritis—especially those who haven’t responded well to other treatments. Evidence shows this gel injection is both effective and safe, providing benefits for at least two years and, in some cases, up to three years.

However, not everyone with knee osteoarthritis is suitable for Arthrosamid. Choosing the right candidates is a careful, evidence-backed process carried out by expert clinicians to ensure the best outcomes and safety.

If you are struggling with knee osteoarthritis symptoms and interested in innovative treatments like Arthrosamid, it’s worth seeking specialist advice. This ensures you receive personalised care tailored to your needs, helping you make informed decisions about your treatment options.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(18), e44655. https://doi.org/10.1097/MD.0000000000044655
• Bliddal, H., Beier, J., Hartkopp, A., Conaghan, P., & Henriksen, M. (2023). Polyacrylamide hydrogel for the treatment of knee osteoarthritis: 3-year follow up results of a prospective clinical study. Annals of the Rheumatic Diseases, 82(Suppl 1), 2104–2105. https://doi.org/10.1136/annrheumdis-2023-eular.6038